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A B S T R A C T
The primary aim of the study was to investigate microcarcinoma characteristics of aggressivity, multicentricity and
metastasis. Though its features are not significantly different from those of other papillary carcinomas, the optimal ther-
apeutic approach continues to be an issue of controversy, most notably appropriate surgical approach and indications for
neck dissection. The study is retrospective analysis of 321 microcarcinoma cases, operated upon with total thyroidectomy,
with or without neck dissection. These cases were compared to larger papillary cancers. We found that 35.1% tumors
were aggressive; 25.2% were multicentric, with foci in the contralateral lobe nearly twice as often as in the ipsilateral
lobe; and 18.2% were metastatic. In comparison to groups of £2 cm and £3 cm, microcarcinomas were less aggressive,
multicentric and metastatic. Male gender and age <45 were unfavorable parameters. Multivariate analysis revealed
contralateral lobe multicentricity and male gender as risk factors for metastasis. Although microcarcinoma demon-
strated better characteristics than larger tumors, this subgroup behaves aggressively and should be approached cau-
tiously.
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Introduction
In recent decades, papillary microcarcinoma has in-
creased in prevalence1–5. Nevertheless, this subgroup is
subject to many controversies, related to risk assess-
ment, therapeutic approach and follow-up6–8. Though
microcarcinoma features are not significantly different
from those of other papillary carcinomas, the optimal
therapeutic approach continues to be an issue of clinical
debate, most notably due to the scarcity of sufficiently
large prospective studies9–12. Ongoing controversies re-
flect limitations of various prognostic systems, as well as
the lack of universally standardized research criteria (in-
consistencies in inclusion criteria and well-defined study
end-points).
While the optimal surgery for high-risk papillary can-
cers has already been well established (total thyroidec-
tomy), the approach to low-risk patients, including mi-
crocarcinomas, is not as clear7,13,14. The appropriate
indications for neck dissection, especially elective neck
dissection, remain to be determined15–18. Low-risk pa-
tients (<45 years, T1 tumors, low histological grade, lack
of distant metastatic spread) currently represent the
largest patient cohort. Recent efforts have attempted to
further improve prognosis through selection of a suitable
surgical approach and appropriate adjuvant therapy18.
Some researchers view microcarcinoma as a less aggres-
sive subtype and advocate a minimalist approach, reserv-
ing intervention (e.g., lobectomy) for when the tumor
turns aggresive18,19. In contrast, other studies point to
aggressive microcarcinoma behavior and higher inci-
dence of bilateral multicentricity, indicating the need for
more aggressive surgery (e.g., near-total thyroidectomy),
supplemented by radioiodine ablation20,21. Despite the
well-recognized characteristics of high-risk papillary
cancers, the majority of studies do not provide clear rec-
ommendations, putting more importance on excellent
prognosis and low incidence of recurrence, focusing on
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the similarities between microcarcinoma and low-risk
papillary carcinoma.
There are not many clinical studies aiming to com-
pare tumor size with pathological aggressivity, i.e., intra-
glandular dissemination and locoregional spread, and
analyze other relevant clinical parameters (choice of
therapy and recurrence)22,23. Tumor aggressivity (nu-
clear atypia, necrosis, lymphovascular invasion) corre-
lates with metastatic spread, independently from tumor
size23. Consequently, histological grade should be viewed
as prognostically important and set as an obligatory com-
ponent of any classification system24.
The primary aim of this study was to investigate se-
lected risk variables (tumor size and aggressivity, multi-
centricity, locoregional spread, age and sex) for micro-
carcinoma and larger tumors, primarily up to 3 cm. We
elaborated several hypotheses: microcarcinoma is prone
to development of multicentric foci and locoregional
spread; multicentricity is not related to size or tumor
aggressivity, and aggressivity and metastatic spread are
linked to age and sex (younger patients and male pa-
tients exhibit more aggressive tumors).
Materials and Methods
This study is a retrospective analysis of clinical and
pathological data from 714 patients with the diagnosis of
papillary thyroid cancer, both sexes, ages 10–86. There
were 321 microcarcinomas. Patients’ data are summa-
rized in Table 1. All patients were operated upon at the
Department of Otolaryngology–Head and Neck Surgery,
»Sestre milosrdnice« University Hospital Center, Zagreb,
Croatia, during the period of 1980–2008. Total thyro-
idectomy, with or without neck dissection (paratracheal
or some type of lateral neck dissection) was performed on
each patient. Data were collected from patient documen-
tation (operative reports, cytological FNAB results, re-
currences, additional thyroid diagnosis), pathology re-
ports, and the Hospital Registry for Thyroid Diseases.
Postoperatively, we followed Diagnostic and therapeutic
guidelines for differentiated thyroid cancer, issued by
Croatian Thyroid Society; postoperative diagnostic scin-
tigraphy were performed with 1–3 mCi 131I. High risk pa-
tients were put to 100–200 mCi 131I ablation without
L-T4. Posttherapeutic whole body scintigraphy were per-
formed 5–8 days after 131I. 6–12 months after, patients
were followed up with neck ultrasound, FT4, TSH, Tg,
TgA (without L-T4), and afterwards yearly.
All patients were assigned to groups for variables of
age, gender, size (diameter) and pathological aggressivity
of the primary tumor, multicentric spread, type of neck
dissection performed and presence of neck metastases.
There were two age groups, younger (<45 years) and
older (³45 years). Separate analysis was performed for
microcarcinoma, as well as tumor sizes of £2 cm and £3
cm. Variables of tumor aggressivity, multicentricity, neck
dissection and metastatic spread were measured in three
degrees of severity, as determined in pathological and op-
erative reports (Table 2). Finally, the possible influence
of other thyroid comorbidities (lymphocytic thyroiditis
and nodular goiter) were examined. Statistical analysis
of differences with c2 test and multivariate logistic re-
gression for measurement of risk factors for metastatic
locoregional spread (gender, age, expansive tm growth
and additional diagnosis) were performed. The statistical
significance level was set at p£0.05.
Results
There were 321 microcarcinoma tumors (£1 cm), rep-
resenting 51.85% of all cases. Rising microcarcinoma
prevalence has been demonstrated during the period
from 1980–1990, 1991–2000, and after the year 2000
(37.1%, 42.9% and 57.1%, respectively). Results showed
that 35.1% of tumors were aggressive; 25.2% were multi-
centric, with foci in the contralateral lobe nearly twice as
often as in the ipsilateral lobe; and 18.2% were meta-
static. Comparison between microcarcinoma and groups
of other primary tumor sizes (£2 cm and £3 cm) is shown
in Table 3.
Tumors >1 cm (1–10 cm) showed significantly more
aggressivity (most notably for group III, 24% vs. 7.5%).
This group displayed more ispilateral and contralateral
multicentric foci. More neck dissections (paratracheal
and lateral) were performed in the group of large tumors,
which also displayed more metastatic spread (paratra-
cheal and lateral). Tumors in the £3 cm group (second
largest subgroup) were also significantly more aggressive
and demonstrated more propensity for multicentric spread
than microcarcinoma. More neck dissections were per-
formed and more metastatic foci were found in this
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TABLE 1
DISTRIBUTION OF PATIENTS WITH PAPILLARY THYROID
CARCINOMA (ALL SIZES; GROUPS) INCLUDED IN STUDY,
OPERATED UPON FROM 1980–2008
Characteristic n=714
Age (yrs)
Range 10–87
Mean
Microcarcinoma (n=321) 48,7 (SD=13.37; SEM=0.04)
£2 cm (n=162) 47,4 (SD=12.17; SEM=0,07)
£3 cm (n=234) 48 (SD=14.05; SEM=0.06)
<45 yr. 282 (40.3%)
³45 yr. 417 (59.7%)
Gender n=714
Female 571 (79.97%)
Male 143 (20.03%)
Size of primary tumor (cm) n=619
Range 0–10
Mean 1.55 (SD=1.35; SEM=0.002)
Microcarcinoma (£1 cm) n=321 (51.9%)
Other (>1 cm) n=298 (48.1%)
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group as well. The third largest subgroup (£2 cm), ac-
counting for 26.5% of all papillary carcinomas, also be-
haved significantly more poorly than microcarcinoma,
showing more aggressivity and tendency for multicentric
spread. There were no differences in the number of neck
dissections performed (p=0.096); differences in meta-
static behavior were only marginally significant (p=0.02).
More microcarcinomas were found in the older age
group (63.3%). No age differences were found for param-
eters of pathological aggressivity (p=0.48), multicentri-
city (p=0.24), or neck dissection (p=0.49). Younger pa-
tients had more paratracheal metastasis (15.2% vs. 7.5%),
and older patients displayed more lateral metastasis (9.1%
vs. 7,7%), but this difference was only marginally signifi-
cant (p=0.09, Table 4). In males, tumors behaved signifi-
cantly more aggressively (p=0.03), with no difference in
multicentricity (p=0.79). Males were more likely to un-
dergo lateral neck dissection (15.2% vs. 9.5%), and fe-
males were more likely to undergo paratracheal neck dis-
section (27.8% vs. 26.1%). Overall, no difference in neck
dissection was observed between the groups (p=0.50).
Furthermore, males had more metastatic foci (p=0.05)
and more paratracheal and lateral metastasis (Table 5).
Hashimoto thyroiditis and nodular goiter were more
prevalent in females, but this trend was not significant
(p=0.18 and p=0.71, respectively).
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TABLE 2
VARIABLES USED IN STUDY; GRADATION BY SEVERITY OF PATHOHISTOLOGICAL FEATURES OF PPRIMARY TUMOR AGGRESSIVITY,
INTRAGLANDULAR DISSEMINATION AND LOCOREGIONAL METASTATIC SPREAD
Gradation
Variables
Pathological aggressivity
of primary tumor
Intraglandular dissemination
(multicentricity)
Neck
dissection*
Locoregional
metastatic spread*
Grade I Sharply demarcated; encapsulated No multicentric foci Not done No metastatic spread
Grade II No clear tumor border; tumor capsule invasion Ipsilateral lobe spread Paratracheal Paratracheal metastasis
Grade III Perivascular, perineural spread; tumor necrosis,
atypical cells; thyroid capsule invasion;
penetration of adjacent soft tissues; fat tissue,
muscle, cartilage invasion
Contralateral lobe spread Lateral Lateral metastasis
* Neck dissection classification from: Robbins KT, Shaha AR, Medina JE, et al.: Consensus Statement on the Classification and Termi-
nology of Neck Dissection. Arch Otolaryngol Head Neck Surg. 2008;134:536–538.
TABLE 3
COMPARISON OF MICROCARCINOMA VS. LARGER PAPILLARY CANCERS (ALL TUMORS, £3 CM, £2 CM)
Characteristic
Primary tumor size groups
£ 1 cm 1–10 cm £3 cm £2 cm
Tumor aggressivity 112/319 (35.1%) 172/293 (58.7%) p=0.0000 130/234 (55.5%) p=0.0000 86/163 (52.7%) p=0.0007
Tumor capsule invasion 88 (27.6%) 100 (34.1%) 84 (35.9%) 64 (39.2%)
Wider aggression 24 (7.5%) 72 (24.6%) 46 (19.6%) 22 (13.5%)
Multicentric spread 80/317 (25.2%) 125/290 (43.1%) p=0.0000 99/235 (42.1%) p=0.0001 65/162 (40.1%) p=0.003
Ipsilateral 29 (9.1%) 43 (14.8%) 35 (14.9%) 25 (15.4%)
Contralateral 51 (16.1%) 82 (28.3%) 64 (27.2%) 40 (24.7%)
Neck dissection 121/319 (37.9%) 145/296 (49%) p=0.01 118/236 (50%) p=0.016 79/164 (48.2%) p=0.096
Paratracheal 88 (27.6%) 96 (32.4%) 83 (35.2%) 58 (35.4%)
Lateral 33 (10.3%) 49 (16.6%) 35 (14.8%) 21 (12.8%)
Metastatic spread 58/318 (18.2%) 92/296 (31%) p=0.001 71/236 (30.1%) p=0.005 47/163 (28.8%) p=0.02
Paratracheal 31 (9.8%) 46 (15.5%) 38 (16.1%) 28 (17.1%)
Lateral 27 (8.4%) 46 (15.5%) 33 (14%) 19 (11.7%)
TABLE 4
COMPARISON OF PATHOLOGICAL PARAMETERS BY AGE
GROUPS (<45 YEARS, ³45 YEARS)
Characteristic
Age <45,
n=117 (36.7%)
Age ³45,
n=202 (63.3%)
p
Tumor aggressivity 44/117 (37.6%) 67/202 (33.2%) p=0.48
Tumor capsule invasion 33 (28.2%) 55 (27.2%)
Wider aggression 11 (9.4%) 12 (5.9%)
Multicentricity 29/117 (24.8%) 51/200(25.5%) p=0.24
Ipsilateral lobe 14 (12%) 15 (7.5%)
Contralateral lobe 15 (12.8%) 36 (18%)
Neck dissection 49/117 (41.9%) 72/200 (36%) p=0.49
Paratracheal 37 (31.6%) 51 (25.5%)
Lateral 12 (10.3%) 21 (10.5%)
Metastatic spread 26/117 (22.2%) 32/199 (16.1%) p=0.09
Paratracheal 17 (14.5%) 14 (7%)
Lateral 9 (7.7%) 18 (9.1%)
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Multivariate analysis of parameters of gender, age, ex-
pansive tm growth and additional diagnosis revealed the
presence of multicentric foci in both lobes to be an inde-
pendent risk factor for locoregional metastatic spread
(OR 2.427), while nodular goiter was identified as a pro-
tective factor (OR 0.453). Tumor aggressivity was not
identified as predictive of locoregional metastatic spread
(Table 6). Age and sex were not identified as important
risk factors.
Discussion
There has been a large volume of papillary micro-
carcinoma research on the important clinicopathological
features of this increasingly encountered subtype of thy-
roid cancer. Research efforts have sought to differentiate
this tumor subtype from larger papillary tumors, as mea-
sured by parameters of primary tumor aggressivity, met-
astatic potential and affinity for locoregional recurrence.
Consensus regarding the optimal therapeutic protocol
would have great impact on the clinical approach as well
as the postoperative follow-up regimen. In this study, we
tried to investigate several pathological and clinical char-
acteristics with which to differentiate papillary cancers
not belonging to the microcarcinoma group (>1 cm). The
majority of papillary carcinomas presented in this study
were microcarcinomas (51.9%). The most notable rise in
prevalence rise (57.1%) was observed during the last de-
cade of study (2001–2008), thereby identifying micro-
carcinoma as the most commonly presented tumor. This
trend of increasing incidence has recently been reported
elsewhere4,7. It is generally accepted that microcarcino-
mas belong to a separate, less aggressive subgroup of
papillary cancers, which exhibit a tendency for benign
clinical behavior and therefore demand a less aggressive
approach. Cheema et al. report excellent disease progno-
sis with low recurrence rates (8%) and 100% survival, at-
tributing favorable results to an initial aggressive ap-
proach (total thyroidectomy in 80% of cases,
accompanied by neck dissection in the case of clinically
significant regional metastatic disease)20.
In contrast, histological grading has been found pro-
gnostically superior to tumor subclassification for evalu-
ation of papillary carcinoma24. Characteristics such as
nuclear atypia, tumor necrosis and lymphovascular inva-
sion are all identified as important factors in evaluation
of tumor aggressivity, recurrence risk, and metastatic
dissemination. For these reasons, we chose tumor ag-
gressivity, multicentricity and metastatic spread as im-
portant clinicopathological variables of papillary cancer
to be measured in our study. We found microcarcinoma
aggressivity in 35.1% of cases. Most aggressivity was in
the form of the absence of a sharp tumor demarcation
and/or tumor capsule invasion (more than two-thirds of
all aggressive cases), and less commonly, wider aggres-
sion (7.5%). Microcarcinomas demonstrated significantly
less aggressivity than tumors >1 cm (1–10 cm), and
slightly less in comparison with the £2-cm and £3-cm
subgroups (both groups had aggressive characteristics in
more than half of the cases). Nonetheless, it can be pos-
tulated that microcarcinoma aggressivity, found in more
than one third of cases, demonstrates signifficant cinical
finding, pointing to similar behaviour as other larger tu-
mors. In contrast to other reports, we distinguished the
gradation of primary tumor aggressivity by differentiat-
ing tumor capsule invasion (grade II) from thyroid gland
capsule invasion (grade III).
Multifocality is a well-known characteristic of papil-
lary cancer, present in 24–30% of cases20,21. This study
demonstrated 25.2% prevalence of multicentric tumors,
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TABLE 5
COMPARISON OF PATHOLOGICAL PARAMETERS BY AGE
GROUP
Characteristic
Males,
n=47 (14.6%)
Females,
n=274 (85.4%)
p
Tumor aggressivity 23/47 (48.9%) 89/272 (32.7%) p=0.03
Tumor capsule invasion 18 (38.3%) 70 (25.7%)
Wider aggression 5 (10.6%) 19 (7%)
Multicentricity 11/46 (23.9%) 69/271 (25.5%) p=0.79
Ipsilateral lobe 3 (6.5%) 26 (9.6%)
Contralateral lobe 8 (17.4%) 43 (15.9%)
Neck dissection 19/46 (41.3%) 102/273 (37.4%) p=0.50
Paratracheal 12 (26.1%) 76 (27.8%)
Lateral 7 (15.2%) 26 (9.5%)
Metastatic spread 13/46 (28.3%) 45/272 (16.5%) p=0.05
Paratracheal 8 (17.4%) 23 (8.5%)
Lateral 5 (10.9%) 22 (8%)
Additional diagnosis
Hashimoto disease 7/47 (14.9%) 65/274 (23.7 %) p=0.18
Nodular goiter 15/47 (31.9%) 95/274 (34.7 %) p=0.71
TABLE 6
RISK FACTORS FOR REGIONAL METASTATIC SPREAD,
LOGISTIC REGRESSION MODEL
OR
95% CL
p
Upper Lower
Gender
Male 1.987 0.97 4.08 0.0614
Female 0.503 0.24 1.03 0.0614
Age (years) 0.976 0.95 1.00 0.0284
Older (45 and older) 0.671 0.38 1.20 0.1758
Multicentricity
No multicentric spread 0.636 0.34 1.18 0.1523
Ipsilateral 0.487 0.14 1.67 0.2524
Contralateral 2.427 1.23 4.79 0.0107
Expansive tm growth
No expansion 0.801 0.45 1.44 0.4591
Tumor capsule invasion 1.209 0.65 2.25 0.5500
Wider aggression 1.187 0.42 3.33 0.7446
Additional diagnosis
Hashimoto disease 1.295 0.67 2.51 0.4434
Nodular goiter 0.453 0.23 0.90 0.0240
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which is in concordance with literature reports. Multi-
centric intrathyroid dissemination suggests a higher pro-
pensity for locoregional spread and higher recurrence
risk6. At the same time, the presence of multiple foci cor-
relates with detailed systematic pathological examina-
tion of thyroid specimens. There are major disagreements
about the significance of multicentricity in papillary can-
cer and microcarcinoma, as well. Many authors, aware of
its high prevalence in both thyroid lobes, advocate total
thyroidectomy as an operation of choice, stating that
more extensive operations decrease the likelihood of re-
currence26. On the other hand, several larger multi-
variate analyses have not identified multicentricity as a
risk factor for recurrence. However, a clear connection
between the presence of multicentricity and metastatic
spread has arguably been revealed. For microcarcinoma,
the importance of multicentricity remains to be investi-
gated effectively, reflecting the problem of clinical mate-
rial diversity, inconsistencies in initial therapeutic ap-
proach and less than detailed pathological examination.
Baudin et al. suggest two important parameters with im-
pact on recurrence: number of histological foci and ex-
tent of initial operation. The authors recommend that
decisions regarding, the extent of surgery should be based
on multifocality findings (i.e., lobectomy in cases of sin-
gle tumor focus and total thyroidectomy plus central
neck dissection for multifocal tumor)18. Our study re-
vealed that 25.2% of microcarcinomas developed multi-
centric foci, with most appearing in the contralateral
lobe (16.1%). Thus multicentricity, when it occurs, is bi-
lateral in more than 60% of multicentric cases. This fact
should be seen in light of earlier studies reporting more
extensive operations (total thyroidectomy vs. lobectomy)
leading to reduced rate of recurrence, 5% vs. 20%, re-
spectively18. On multivariate analysis, multicentricity was
found to be the single most important risk factor for de-
velopment of metastatic spread (OR 2.427). Even stron-
ger association was evident for tumors >1 cm (OR 3.119).
In both cases, the correlation applies to the presence of
one or more multicentric foci in the contralateral lobe.
Interpretation of this finding strongly signifies the need
for an initially cautious surgical approach, incorporating
complete removal of the contralateral lobe in suspicious
cases. We should underline that this surgical approach
(total thyroidectomy) has been part of our surgical proto-
col throughout the entire period of study, significantly
contributing to quality analysis of intraglandular tumor
spread.
Locoregional metastatic spread is one of the most im-
portant risk factors preceding distant dissemination, with
reported frequency of 3.1–18.2%27,28. We found that mi-
crocarcinoma are prone to metastatic behavior, with pre-
valence of 18.2%. In 53% of cases, the paratracheal re-
gion was the only site of metastatic growth; lateral
regions were involved in 47% of cases. The distribution of
locoregional spread followed well-known pathways of
lymphatic drainage, with the paratracheal region being
involved most commonly. Even though we found that
microcarcinoma exhibited significantly less metastatic
potential, we have demonstrated that regional meta-
static spread is directly dependent on tumor size,
without a clear-cut size margin. This observation once
again addresses the importance of preoperative neck di-
agnostics and careful intraoperative neck exploration.
We also found that the chance of metastatic spread is in-
creased in cases of multicentricity by more than two-fold.
Our findings basically agree with those reported by Hay
et al., emphasizing higher relative recurrence risk for
metastasizing papillary carcinomas29.
Patient age is an important independent prognostic
predictor, incorporated in TNM as well as many other
classification systems, marking patients less than 45
years of age as low risk and patients older than 45 as a
high risk30. In the present study, we demonstrated rela-
tively worse behavior in the younger group, across all of
the measured variables, except for multicentricity. Tu-
mors in the younger subpopulation were slightly more
aggressive, with no statistical significance (37.6% vs.
33.2%, p=0.48). Differences between age groups became
more evident when metastatic potential was examined,
with the younger group having a higher frequency of
metastatic spread (22.2% vs. 16.1%, p=0,09). This some-
what higher aggressivity in the younger group does not
necessarily represent worse prognosis in terms of specific
survival, more commonly present in the older popula-
tion31. We confirmed these findings in larger tumors as
well, a finding that was generally not in accordance with
the majority of other studies, which found more ag-
gressivity among the older population25. Regarding gen-
der, microcarcinoma pathological aggressivity (48.9% vs.
32.7%), as well as metastatic dissemination in all neck re-
gions (22.7% vs. 16,1%) were significantly worse parame-
ters in males, while multicentricity was similar in males
and females. These differences were even more evident
among patients with larger tumors. This is in accordance
with the relatively low number of related studies that
have demonstrated gender as an independent risk factor
for recurrence and identified the prognostic importance
of male gender (higher estimated risk for multiple recur-
rences and unsuccessful salvage surgery)32,33.
To date, many multivariate studies on papillary carci-
nomas have been published in an attempt to analyze the
impact of potentially important prognostic factors. The
most commonly differentiated factors are age, tumor
grade and extension (extrathyroid invasion, distant meta-
stases, and, less commonly, regional metastases). Several
scoring systems have evolved, in an effort to stratify
prognostic risk between low- and high-risk patients. The
spectrum of recommended surgical options for microcar-
cinoma is broad, including total thyroidectomy, near-to-
tal thyroidectomy, subtotal thyroidectomy and lobectomy
with isthmusectomy. The most minimal approach is clini-
cal observation and periodical follow-up, with indications
for therapeutic intervention only when the tumor turns
more aggressive34. The American Thyroid Association
advises lobectomy for small, low-risk cancers without
metastatic spread, while total thyroidectomy is advised
for cases of multifocality and metastatic spread. The
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British Thyroid Association made similar recommend-
ations35–37. However, some authors favor a more aggres-
sive approach to microcarcinoma (total thyroidectomy
accompanied by ablative therapy), similar to the ap-
proach used for other, larger tumors. Some investigators
suggest that tumors with unusual microscopic character-
istics, capsule invasion, lymphovascular extension or tall-
-cell subtype should be included in separate groups. Such
authors assert increased aggressivity to be more fre-
quent in patients of younger age and male sex, as demon-
strated in our study. In summary, microcarcinomas show
clinicopathological characteristics that do not separate
them exclusively from other papillary carcinomas38. We
do not support the claim that more aggressive surgery
(total thyroidectomy) is associated with more morbidity,
because perioperative morbidity was very low (below
1%). Further, the fact that multicentric tumors, when
they occur, arise in the contralateral lobe in 60% of cases,
point to the need to extend surgery to the other lobe,
thereby eliminating the most common site of possible fu-
ture recurrence. With high incidence of paratracheal and
lateral metastasis, it is necessary to perform meticulous
intraoperative neck exploration in search of suspicious
lymph nodes and to perform neck dissection (paratrach-
eal and/or lateral) at the same time as thyroid gland sur-
gery, when deemed necessary. Future research should
elucidate the precise therapeutic guidelines to be used
for this commonly encountered thyroid tumor.
Conclusion
Even though our study identified microcarcinoma as
a tumor with clinical and pathological characteristics
better to those of larger tumors, we can conclude that
papillary thyroid microcarcinoma behaves aggressively,
in many ways, primarily in comparison with tumors up
to 3 cm, and therefore recommend a cautious clinical ap-
proach.
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PAPILARNI MIKROKARCINOM [TITNJA^E: KLINI^KA I PATOLO[KA STUDIJA 321 SLU^AJA
S A @ E T A K
Osnovni cilj studije bio je istra`iti patolo{ku agresivnost, multicentri~nost i metastatske osobitosti papilarnog mikro-
karcinoma {titnja~e. Postavljene su hipoteze da je mikrokarcinom sklon pojavi multicentri~nih `ari{ta tumora i loko-
regionalnom {irenju; multicentri~nost nije povezana sa veli~inom niti agresivno{}u tumora; agresivnost i metastatsko
{irenje povezano je sa dobi i spolom. Metode: retrospektivna analiza 321 slu~aja mikrokarcinoma, operiranih totalnom
tireoidektomijom sa ili bez disekcije vrata. Svi slu~ajevi usporedjeni su sa papilarnim karcinomima ve}e veli~ine primar-
nog tumora. Rezultati: 35,1% tumora je bilo agresivno; 25,2% je pokazalo multicentri~nost, sa `ari{tima u kontralate-
ralnom re`nju pribli`no dvostruko ~e{}e nego u ipsilateralnom re`nju; 18,2% tumora je metastaziralo lokoregionalno.
U usporedbi sa odvojenom grupom tumora od £2 cm and £3 cm, mikrokarcinomi su bili manje agresivni, multicentri~ni
i metastatski. Mu{ki spol i dob <45 godina pokazani su kao nepovoljni klini~ki parametri. Multivarijantna analiza
pokazala je postojanje multicentri~nih `ari{ta u kontralateralnom re`nju te mu{ki spol kao rizi~ne ~imbenike za pojavu
metastaza. Zaklju~ak: premda je mikrokarcinom u ovoj studiji pokazao bolje klini~ko pona{anje od papilarnih karci-
noma veli~ine ve}e od 1 cm, ova podgrupa tumora pona{ala se zna~ajno agresivno te savjetujemo nu`ni oprez u klini-
~kom pristupu ovoj zna~ajnoj podgrupi pacijenata.
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